Bristol Myers Squibb (NYSE: BMY) stock was a rare bright light on a very dim Thursday for American equities. Encouraged by the company's good quarterly and annual earnings release, market players pushed the stock up by more than 3% on a day when the S&P 500 index slumped by more than 1%. Newer products carried the day Bristol Myers' fourth quarter of 2025 saw the veteran pharmaceutical company grow revenue by 1% year over year to $12.5 billion. Much of this was attributable to its so-called "growth portfo ...

Core Viewpoint - Bristol Myers Squibb reported strong fourth quarter results and issued a 2026 forecast that exceeded Wall Street expectations, indicating potential for continued stock momentum in current market conditions [1] Financial Performance - Fourth quarter revenue increased by 1% to $12.5 billion, surpassing the expected $12.28 billion [1] - Earnings per share (EPS) fell 25% year over year to $1.26 but exceeded estimates of $1.12 [1] - Bristol Myers' shares rose over 1.5% despite a down day for the S&P 500, reflecting the stock's defensive nature [1] Product Performance - The new schizophrenia treatment Cobenfy has significant sales potential, although it is still in early stages [1] - Sales of the blood thinner Eliquis, the company's largest drug, increased by 8% annually, despite falling short of expectations [1] - Bristol Myers expects Eliquis sales to grow by 10% to 15% for the full year, contrary to analyst expectations of a 15% decline in 2026 [1] Cost Management - The company achieved a half percentage point of adjusted operating margin expansion due to cost-cutting efforts, with both research-and-development costs and overhead expenses declining year over year [1] - Bristol is on track to deliver approximately $1 billion in cost savings in 2025 and another $1 billion over the next two years [1] Future Outlook - Bristol Myers provided 2026 revenue guidance of $46 billion to $47.5 billion, better than the $44.16 billion expected [1] - Gross margin is projected to be 69% to 70%, below the FactSet consensus of 72.3% [1] - Adjusted earnings are expected to be between $6.05 and $6.35 per share, exceeding the $6.02 expected [1] - The company anticipates a busy year of trial readouts, with over 10 late-stage study updates expected, which could bolster investor confidence [1]

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Thursday.The Dow traded down 0.86% to 49,073.13 while the NASDAQ dipped 1.03% to 22,669.07. The S&P 500 also fell, dropping, 0.91% to 6,820.34.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsReal estate shares gained by 0.1% on Thursday.In trading on Thursday, materials stocks fell by 2.2%.Top HeadlineBristol Myers Squibb & Co. (NYSE:BMY) ...

Company Performance - Bristol Myers Squibb & Co. reported fourth-quarter 2025 revenues of $12.50 billion, exceeding the consensus estimate of $12.281 billion, representing a 1% year-over-year increase [2] - The company reported adjusted earnings of $1.26, surpassing the consensus of $1.11, although this reflects a 25% decline due to the impacts of acquired IPRD charges and licensing income [2] Market Trends - U.S. stocks experienced a decline, with the Dow Jones index falling more than 400 points, down 0.86% to 49,073.13, while the NASDAQ dipped 1.03% to 22,669.07, and the S&P 500 dropped 0.91% to 6,820.34 [1] - In commodity markets, oil prices decreased by 2.5% to $63.51, gold fell by 0.9% to $4,907.60, silver dropped 9.4% to $76.455, and copper declined 0.5% to $5.8210 [3]

Core Insights - Bristol Myers Squibb (BMY) stock experienced a moderate rise following the announcement of adjusted earnings of $1.26 per share, surpassing analyst expectations of $1.23 per share [1] - The company reported fourth-quarter sales of $12.5 billion, exceeding the anticipated $12.28 billion [1] - In comparison to the previous year, Bristol Myers earned $1.67 per share on $12.34 billion in sales during the same period [1] Financial Performance - Adjusted earnings per share: $1.26, compared to analyst expectations of $1.23 [1] - Fourth-quarter sales: $12.5 billion, exceeding the forecast of $12.28 billion [1] - Year-over-year comparison: Previous year earnings were $1.67 per share on $12.34 billion in sales [1]

Core Insights - Bristol-Myers Squibb Company (BMY) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.26, exceeding the Zacks Consensus Estimate of $1.15, but down from $1.67 in the same quarter last year [1] - Total revenues reached $12.5 billion, surpassing the Zacks Consensus Estimate of $12.25 billion, and reflecting a 1% increase from the previous year [1] - The stock price increased following the better-than-expected quarterly results [1] Financial Performance - BMY's shares have increased by 28.5% over the past six months, while the industry has grown by 43.8% [2] - U.S. revenues remained flat year over year at $8.56 billion, while international revenues rose by 5% to $3.94 billion [3] - The Growth Portfolio revenues increased by 16% to $7.39 billion, primarily driven by immuno-oncology drugs like Opdivo [6][7] - The Legacy Portfolio revenues decreased by 15% to $5.11 billion, impacted by generic competition on key drugs, despite an 8% increase in Eliquis sales to $3.45 billion [11] Key Drug Performance - Opdivo sales increased by 9% year over year to $2.69 billion, surpassing estimates [8] - Yervoy contributed $810 million, up 20% year over year, and Reblozyl sales surged 22% to $666 million [9] - Breyanzi sales rose by 49% to $392 million, while Camzyos sales skyrocketed by 59% to $353 million [10] Cost and Margin Analysis - Adjusted gross margin decreased to 71.9% from 74% in the previous year due to a change in product mix [14] - Adjusted research and development expenses declined by 8% to $2.56 billion, and adjusted marketing, selling, and administrative expenses decreased by 1% to $2.09 billion [15] Future Guidance - For 2026, BMY provided revenue guidance of $46-$47.5 billion, supported by the Growth Portfolio's strong performance [17] - The company expects adjusted earnings to be in the range of $6.05-$6.35 for the full year, with the Zacks Consensus Estimate for 2026 EPS at $6.08 [17] Pipeline Updates - In December 2025, the FDA approved Breyanzi for adult patients with relapsed or refractory marginal zone lymphoma [18] - A supplemental biologics license application for Opdivo in combination with other drugs for Hodgkin lymphoma is under priority review, with a decision expected by April 8, 2026 [19]

上海医药"清仓"30%股权 随后，BMS发言人证实，该次出售主要涉及在中国生产的成熟药品和消费产品，不影响BMS在中国的 核心创新药物业务。不过，该发言人没有透露买家身份以及协议的财务条款。 上海医药在本次公告中，对上述情况进行了印证。公告称，百时美施贵宝（中国）投资有限公司拟对外 出售其持有的中美施贵宝60%股权，经多轮竞标与谈判，潜在收购方于2025年6月提交确认性报价，拟 以4.8亿美元的等值人民币收购中美施贵宝的100%股权。其中，上海医药持有的30%股权对应价格为 1.44亿美元。 不过，上海医药认为在市场化报价下实现股权退出更能够实现资产价值最大化、维护全体股东特别是中 小股东的利益。公告称，以评估基准日（2025年9月30日）中国人民银行发布的人民币对美元汇率中间 价7.1055为准，拟定挂牌底价为人民币10.23亿元（需完成相关国有评估管理程序），最终转让价格以公 开挂牌成交结果为准。 就股权转让等相关问题，北京商报记者向上海医药发送采访函，但截至发稿未获得回复。 营收较巅峰期缩水超60% 超40年合资历程，中美上海施贵宝制药有限公司（以下简称"中美施贵宝"）走向重组。2月4日晚，上海 医药发 ...

Group 1: Jobless Claims Data - Initial Jobless Claims reached 231K, exceeding expectations of 212K and the previous week's 209K, marking the highest level of 2026 so far [2] - Continuing Claims increased to 1.844 million from a revised 1.819 million the prior week, still favorable compared to the past six months where it ranged between 1.93 and 1.97 million [3] Group 2: Earnings Reports - Bristol Myers-Squibb (BMY) reported earnings of $1.26 per share, beating the Zacks consensus of $1.15, resulting in a 9.57% earnings beat, with shares up 1.7% [4] - ConocoPhillips (COP) missed earnings estimates by 6 cents, reporting $1.02 per share, leading to a 5.6% earnings miss and a 3.3% drop in shares [5] - Ralph Lauren (RL) posted earnings of $6.22 per share, surpassing expectations of $5.80 with a 7.2% positive surprise, although shares fell 6.5% due to declining annualized revenue growth [6] - Tapestry (TPR) reported earnings of $2.69 per share, exceeding the Zacks consensus of $2.20, with shares up 5.9% [7] - Other notable earnings beats included Hershey's (HSY) at +21.28% and ArcelorMittal (MT) at +53.57%, while MasterCraft Boat (MCFT) had the largest beat at +81.25%, despite a revenue miss leading to a 1.2% drop in shares [8]

Core Insights - Bristol Myers Squibb reported fourth-quarter 2025 revenues of $12.50 billion, exceeding the consensus estimate of $12.281 billion, marking a 1% year-over-year increase [1] - The company highlighted significant progress in 2025, with a strong Growth Portfolio and a robust balance sheet, allowing for continued investment in growth drivers [1] Financial Performance - Adjusted earnings for Bristol Myers Squibb were reported at $1.26, surpassing the consensus of $1.11, although this reflects a 25% decline due to acquired IPRD charges and licensing income [2] - The Growth Portfolio generated revenues of $7.4 billion, a 16% increase (15% at constant currency), primarily driven by the immuno-oncology portfolio, Camzyos, Breyanzi, and Reblozyl [3] - Legacy Portfolio revenues decreased to $5.1 billion, a 15% decline (16% Ex-FX), with increased demand for Eliquis offset by generic impacts and higher U.S. government channel rebates [3] Product Sales - Eliquis sales reached $3.45 billion, an 8% increase [4] - Opdivo sales increased by 9% to $2.69 billion, while Orencia generated $1.01 billion in sales, up 1% [4] - Yervoy sales rose by 20% to $810 million, and Reblozyl saw a 22% increase in quarterly sales to $666 million [4] Future Outlook - For fiscal 2026, Bristol Myers Squibb expects adjusted earnings of $6.05-$6.35 per share, compared to the consensus of $6.02 [5] - The company anticipates 2026 sales of approximately $46 billion-$47.50 billion, exceeding the consensus of $44.16 billion, with a projected revenue decline of 12-16% for the Legacy Portfolio, partially offset by the Growth Portfolio [5] - Global Eliquis revenues are expected to increase by 10%-15% in 2026 [5] - The company projects a gross margin of around 69-70%, influenced by product mix changes [6]

Core Insights - The company demonstrated strong fourth-quarter performance in 2025, with a growth portfolio that increased by 15% year-over-year, contributing significantly to overall revenue [1][15] - The company is focused on executing a multiyear plan aimed at long-term growth, entering 2026 with positive momentum [1][12] - The company anticipates 2026 revenue between $46 billion and $47.5 billion, driven by strong performance from its growth portfolio despite a projected decline in its legacy portfolio [12][13] Financial Performance - Total revenue for Q4 2025 was approximately $12.5 billion, with the growth portfolio accounting for nearly 60% of total revenue [15] - Key brands such as Reblozyl, Breyanzi, and Camzyos showed significant growth, with Breyanzi's revenue up 47% and Camzyos growing 57% [18][19] - The company achieved approximately $1 billion in cost savings in 2025, with plans to realize an additional $1 billion in 2026 and 2027 [20][49] Product Development and Pipeline - Breyanzi received FDA approval for additional cancer types, enhancing its market position [6] - The company has multiple pivotal studies planned for 2026, with expectations for significant data readouts that could enhance the growth profile of its portfolio [10][30] - The company is focusing on expanding its product offerings in oncology, immunology, and neuroscience, with several new medicines expected to launch by 2030 [8][11] Market Dynamics - Eliquis is projected to grow by 10% to 15% in 2026, driven by increased global demand and a recent price reduction that enhances patient access [13][40] - The company anticipates a revenue decline of $1.5 billion to $2 billion for Eliquis in 2027 due to generic competition, which is expected to impact its overall revenue [25][82] - The company is strategically focused on business development opportunities that align with its existing therapeutic areas, while also considering new market expansions [39][44]